|
市場調査レポート
商品コード
1074804
ワクチンアジュバントの世界市場:タイプ別、製品別、疾患タイプ別、地域別の分析-予測(~2028年)Vaccine Adjuvants Market Forecasts to 2028 - Global Analysis By Type (Virus-like Particles, Tensoactive Adjuvants, Organic Adjuvants), Product (Adjuvant Emulsions, Combination Adjuvants), Disease Type (Cancer, Infectious Diseases) and By Geography |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
ワクチンアジュバントの世界市場:タイプ別、製品別、疾患タイプ別、地域別の分析-予測(~2028年) |
出版日: 2022年05月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
世界のワクチンアジュバントの市場規模は、2021年に7億9,100万米ドルとなり、予測期間中は14.5%のCAGRで成長し、2028年には20億4,087万米ドルに達すると予測されています。
当レポートでは、世界のワクチンアジュバント市場について調査分析し、市場の促進要因、抑制要因、タイプ・製品・疾患タイプ・作用メカニズム・投与経路・用途・エンドユーザー・地域別市場分析、企業プロファイルに関する情報を提供しています。
Table18 Global Vaccine Adjuvants Market Outlook, By Disease Type (2020-2028) (US $MN)
Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $791.00 million in 2021 and is expected to reach $2,040.87 million by 2028 growing at a CAGR of 14.5% during the forecast period. Adjuvants are fundamentally compounds that improve the body's immunogenic reaction against antigens. As a result, these are majorly added to vaccines to increase their capability to influence long-term protection and safety against any kind of viruses. Currently, MF59 and aluminum salts are the only adjuvants which are viable for human usage. There have been a lot of developments done on the antigen discovery over the past decade which has enhanced the vaccine development process.
Market Dynamics:
Driver:
Rising Incidence of Naive Infectious Chronic Diseases
The upsurge in the prevalence of cervical cancer, infectious diseases like Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases are predicted to drive the market. Moreover, in recent years there has been an increasing focus on developing more efficient and longer-lasting vaccination against current and new diseases. The current onset of the Covid-19 pandemic is expected to create massive growth opportunities for the development of the global market. The research and development activities for creating a vaccine for Covid-19 have been underway at full force. With over a million cases across the globe and more than 160 countries affected, it has become imperative to find a vaccine for the infection. This will present a promising demand for the overall development of the market.
Restraint:
High Cost of Raw material
The increasing costs of the raw materials which in turn have lifted the cost of manufacturing are a few of the factors hindering the growth of the market. The cost of developing new vaccine adjuvants, the high toxicity of adjuvants on application, huge investment required for developing a new adjuvant, and strict regulatory requirements are some restraining factors that are expected to hamper the global vaccine adjuvants market growth.
Opportunity:
Increasing Research & Development
Increased levels of spending and funding allocated for the development of more efficient vaccine adjuvants. The regional segment of Western Europe and the APEJ segment is next in line after North America in terms of revenue generation. Increasing government initiatives for vaccinations and the high prevalence of infectious & zoonotic diseases are accelerating the growth of the market. An increasing technological advancement focusing on improved & long-lasting vaccines for existing and emerging chronic diseases is creating ample opportunity for the market.
Threat:
Side Effects
Adjuvanted vaccines can cause more local reactions (such as redness, swelling, and pain at the injection site) and more systemic reactions (such as fever, chills, and body aches) than non-adjuvanted vaccines. Side effects of adjuvants will further derail the market growth rate. The high manufacturing cost of these drugs will also create hindrances to the growth of this market.
Particulate Adjuvants segment is expected to be the largest during the forecast period
The Particulate segment is expected to hold the largest market share while adjuvant emulsion segment is predicted to grow with the highest CAGR. The factors can be attributed to the growing prevalence of diseases such as allergy, cancer, & HIV/AIDS, development of improved vaccine immunization, and rising demand for advanced treatment options.
The Intramuscular Route segment is expected to have the highest CAGR during the forecast period
The intramuscular Route segment is driven by owing to rapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc.
Region with highest share:
The Asia Pacific is projected to hold the highest market share. The growth in this market cantered at China and India. Increasing incidence of infectious diseases, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian province. Moreover, the continuously improving healthcare facilities such as the availability of medicines, coupled with the increase in research & development funding to meet the huge unmet demands. This is expected to increase the market share over the forecast period.
Region with highest CAGR:
North America is projected to have the highest CAGR, owing to high adoption of the innovative products and incidence of major market players in this province especially in the United States. Further, favourable government support towards the growth of healthcare infrastructure is also contributing the growth of the vaccine adjuvants market in this region.
Key players in the market:
Some of the key players profiled in the Vaccine Adjuvants Market include Adjuvance Technologies, Inc, Adjuvatis, Agenus, Inc, Aphios Corp, Avanti Polar Lipids, CSL Limited, CureVac AG, GSK, Invivogen, Kineta, Inc, MVP Laboratories, Inc, Novartis/CSL, Novavax, Inc, OZ Biosciences, Sergeant Adjuvants, Sigma Aldrich (Merck KGaA), Vaxine Pty Ltd, Vaxliant, Viscogel AB, Sanofi, SK bioscience.
Key developments:
In February 2022: Sanofi and GSK intends to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.
In August 2021: SK bioscience and GlaxoSmithKline plc (GSK) initiated a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination with GSK's pandemic adjuvant following positive interim Phase 1/2 results..
Types Covered:
Products Covered:
Disease Types Covered:
Mechanism of Actions Covered:
Route of Administrations Covered:
Applications Covered:
End Users Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options: